Development of a DUX4 -targeting antibody oligonucleotide conjugate as a therapy for FSHD
Nucleic Acids Research · 13.04.2026 · 54 (7)
DOI: 10.1093/nar/gkag301 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 17.04.2026. Verfasst von Barbora Malecova und 15 weiteren Autor:innen. Beteiligte Einrichtung: Avidity Biosciences, Inc., 3020 Callan Rd, San Diego, CA 92121, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Facioscapulohumeral, Homeodomain Proteins, RNA, Small Interfering, Immunoconjugates. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Avidity Biosciences, Inc.
Abstract (Originalsprache)
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant muscular disease in which genetic mutations activate DUX4 expression in skeletal muscle. Currently, there are no approved therapies for FSHD. We developed Delpacibart braxlosiran (del-brax, also known as AOC 1020), an antibody oligonucleotide conjugate (AOC), for the treatment of FSHD that is designed to specifically target and reduce DUX4 mRNA in skeletal muscle. AOC 1020 is composed of DUX4 mRNA-targeting small interfering RNA (siRNA), siDUX4.6, conjugated to a human transferrin receptor 1 (TfR1)-targeting monoclonal antibody to facilitate productive siRNA delivery to muscle. We demonstrate that siDUX4.6 reduces DUX4-regulated gene expression in FSHD patient-derived myotubes in vitro and in skeletal muscle of the ACTA1-MCM; FLExDUX4 FSHD mouse model in vivo. Single systemic intravenous treatment was sufficient to prevent DUX4-induced muscle weakness and fibrosis in this FSHD mouse model and reduce DUX4-regulated genes by ∼75% 8 weeks post-dose. The pharmacokinetic profiles of AOCs with siDUX4.6 were comparable in murine and non-human primate muscle. These data demonstrate the potential of AOC 1020 to treat the underlying cause of FSHD by suppressing DUX4 expression in muscles of patients with FSHD. The safety and efficacy of AOC 1020 is currently being investigated in clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Avidity Biosciences, Inc., 3020 Callan Rd, San Diego, CA 92121, USA.
Förderung
- Avidity Biosciences, Inc
Zitieren
APA
Malecova, B., Sala, D., Melikian, G. M., Johns, R., Erdogan, G., Hartmann, M., Jordan, M., Arias, J. D., Bhattacharya, A., Meng, Q., Dansereau, O., Beppler, S. W., Doppalapudi, V. R., Huang, H., Flanagan, W. M., & Levin, A. A. (2026). Development of a DUX4 -targeting antibody oligonucleotide conjugate as a therapy for FSHD. Nucleic Acids Research, 54(7). https://doi.org/10.1093/nar/gkag301
Vancouver
Malecova B, Sala D, Melikian GM, Johns R, Erdogan G, Hartmann M, et al. Development of a DUX4 -targeting antibody oligonucleotide conjugate as a therapy for FSHD. Nucleic Acids Research. 2026;54(7). doi:10.1093/nar/gkag301
BibTeX
@article{Malecova2026,
author = {Malecova, Barbora and Sala, David and Melikian, Garineh M and Johns, Rachel and Erdogan, Gulin and Hartmann, Marc and Jordan, Maryam and Arias, Joel Danny and Bhattacharya, Arvind and Meng, Qingying and Dansereau, Oliver and Beppler, Samuel W and Doppalapudi, Venkata R and Huang, Hanhua and Flanagan, William Michael and Levin, Arthur A},
title = {Development of a DUX4 -targeting antibody oligonucleotide conjugate as a therapy for FSHD},
journal = {Nucleic Acids Research},
year = {2026},
volume = {54},
number = {7},
doi = {10.1093/nar/gkag301}
}
EUVIMED